Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Effect of amiodarone therapy on the time course of myocardial phospholipid hydrolysis during in vitro total ischaemia in cat hearts

Identifieur interne : 002E39 ( Main/Exploration ); précédent : 002E38; suivant : 002E40

Effect of amiodarone therapy on the time course of myocardial phospholipid hydrolysis during in vitro total ischaemia in cat hearts

Auteurs : Nisar A. Shaikh [Canada]

Source :

RBID : ISTEX:0F1479CA463F91A1600360B7A7C0731E37661866

English descriptors

Abstract

Abstract: The effects of chronic amiodarone therpy oon myocardial phospholipid hydrolysis induced by total in vitro ischaemia were investigated in cat hearts. Chronic treatment of cats with amiodarone (30 mg/kg/day, orally) for 6 weeks resulted in a sufficient uptake of the drug reaching tissue levels of 83 ± 13 & 122 ± 22 μm (n = 12) for amiodarone and its principle metabolite, desethylamiodamine, respectively. This was accompanied by a significant increase (37%, P<0.001) in total phospholipid content of heart in treated as compared to untreated animals. Upon in vitro total ischaemia, these endogenous drug levels were sufficient to attenuate significantly hydrolysis of membrane phospholipid. The degree of attenuation was dependent upon the duration of ischaemic insult. In this regard, protection against phospholipid losses by amiodarone treatment was significantly more in the later irreversible phase of ischaemic injury whether studied in an in vitro total ischaemia model or in an isolated perfused heart preparation. Similar trend was observed in the relative accumulation of lysophospholipid and non-esterified fatty acid levels during ischaemia, i.e. both were significantly attenuated by amiodarone treatment. However, in contrast to the fatty acid data, the net changes in lysophospholipids per gram tissue wet weight were similar in treated and untreated animals, suggesting that the protective effects of amiodarone may have involved other enzymes including phospholipase C and D. Also, during the entire time course studied, all the phospholipid classes appeared to be affected to more or less a similar degree, indicating that the effects of the drug may have manifested in other subcellular compartments besides lysosommes. However, at all time periods studied, the net release of eicosatetraenoic and docosahexaenoic acid (fatty acids occupying primarily sn-2 position of phospholipids) was different, release of the former fatty acid being inhibited more than the latter, suggesting specific interaction of amiodarone with the molecular species of phospholipid. The data suggest that amiodarone attenuates ischaemia-induced membrane lipid abnormalities in part through modulation of phospholipid metabolism, and that this effect may be one of the key determinants which contribute to its antiarrhythmic properties during acute ischaemia.

Url:
DOI: 10.1016/0022-2828(92)91840-2


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Effect of amiodarone therapy on the time course of myocardial phospholipid hydrolysis during in vitro total ischaemia in cat hearts</title>
<author>
<name sortKey="Shaikh, Nisar A" sort="Shaikh, Nisar A" uniqKey="Shaikh N" first="Nisar A." last="Shaikh">Nisar A. Shaikh</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0F1479CA463F91A1600360B7A7C0731E37661866</idno>
<date when="1992" year="1992">1992</date>
<idno type="doi">10.1016/0022-2828(92)91840-2</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-CC8GJMVS-4/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001A31</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001A31</idno>
<idno type="wicri:Area/Istex/Curation">001A31</idno>
<idno type="wicri:Area/Istex/Checkpoint">001C12</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001C12</idno>
<idno type="wicri:doubleKey">0022-2828:1992:Shaikh N:effect:of:amiodarone</idno>
<idno type="wicri:Area/Main/Merge">002F05</idno>
<idno type="wicri:Area/Main/Curation">002E39</idno>
<idno type="wicri:Area/Main/Exploration">002E39</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Effect of amiodarone therapy on the time course of myocardial phospholipid hydrolysis during in vitro total ischaemia in cat hearts</title>
<author>
<name sortKey="Shaikh, Nisar A" sort="Shaikh, Nisar A" uniqKey="Shaikh N" first="Nisar A." last="Shaikh">Nisar A. Shaikh</name>
<affiliation wicri:level="4">
<country>Canada</country>
<wicri:regionArea>Department of Medicine, University of Toronto, Room 7358, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Journal of Molecular and Cellular Cardiology</title>
<title level="j" type="abbrev">YJMCC</title>
<idno type="ISSN">0022-2828</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1992">1992</date>
<biblScope unit="volume">24</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="507">507</biblScope>
<biblScope unit="page" to="521">521</biblScope>
</imprint>
<idno type="ISSN">0022-2828</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0022-2828</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>1ysopl</term>
<term>1ysopl levels</term>
<term>Acute ischaemia</term>
<term>Acyl</term>
<term>Alkenyl species</term>
<term>Amiodarone</term>
<term>Amiodarone therapy</term>
<term>Amiodarone treatment</term>
<term>Amphiphilic lipids</term>
<term>Ample evidence</term>
<term>Antiarrhythmic</term>
<term>Antiarrhythmic agent</term>
<term>Attenuated</term>
<term>Bacterial phospholipase</term>
<term>Beneficial effects</term>
<term>Biochem biophys</term>
<term>Biol chem</term>
<term>Biopsy</term>
<term>Cardiac ischemia</term>
<term>Cardiol</term>
<term>Cell biochem</term>
<term>Cell cardiol</term>
<term>Chronic treatment</term>
<term>Circ</term>
<term>Coronary artery occlusion</term>
<term>Different compartments</term>
<term>Different periods</term>
<term>Downar</term>
<term>Early phase</term>
<term>Electrophysiological</term>
<term>Electrophysiological properties</term>
<term>Endogenous drug</term>
<term>Entire time course</term>
<term>Fatty acid</term>
<term>Fatty acid levels</term>
<term>Fatty acids</term>
<term>Further work</term>
<term>Global ischaemia</term>
<term>Haemodynamic effects</term>
<term>Heart homogenates</term>
<term>Heart model</term>
<term>Heart preparations</term>
<term>Hydrolysis</term>
<term>Infarct size</term>
<term>Intact heart biopsies</term>
<term>Internal standards</term>
<term>Irreversible phase</term>
<term>Ischaemia</term>
<term>Ischaemia model</term>
<term>Ischaemic</term>
<term>Ischaemic heart</term>
<term>Ischaemic injury</term>
<term>Ischaemic insult</term>
<term>Ischemia</term>
<term>Ischemic</term>
<term>Latter study</term>
<term>Lipid</term>
<term>Lipid amphiphiles</term>
<term>Lysophospholipid</term>
<term>Lysophospholipid accumulation</term>
<term>Lysosomal</term>
<term>Lysosomal enzymes</term>
<term>Lysosomal phospholipases</term>
<term>Lysosome</term>
<term>Membrane</term>
<term>Membrane bilayer</term>
<term>Membrane dysfunction</term>
<term>Membrane integrity</term>
<term>Membrane phospholipids</term>
<term>Molecular species</term>
<term>More hours</term>
<term>Myocardial</term>
<term>Myocardial ischaemia</term>
<term>Myocardial phospholipid hydrolysis</term>
<term>Myocardium</term>
<term>Nefa</term>
<term>Nefa levels</term>
<term>Occlusion</term>
<term>Organelle</term>
<term>Other compartments</term>
<term>Other enzymes</term>
<term>Other subcellular organelles</term>
<term>Percentage increase</term>
<term>Percentage losses</term>
<term>Perfused retrogradely</term>
<term>Phospholipase</term>
<term>Phospholipase activities</term>
<term>Phospholipase inhibition</term>
<term>Phospholipases</term>
<term>Phospholipid</term>
<term>Phospholipid classes</term>
<term>Phospholipidosis</term>
<term>Porcine heart</term>
<term>Previous studies</term>
<term>Protective effects</term>
<term>Sequential lysosomal alterations</term>
<term>Shaikh</term>
<term>Significant attenuation</term>
<term>Significant losses</term>
<term>Significant significance</term>
<term>Snake venom phospholipase</term>
<term>Subcellular</term>
<term>Time course</term>
<term>Time increase accumulation</term>
<term>Tissue levels</term>
<term>Total ischaemia</term>
<term>Total ischaemia model</term>
<term>Total ischemia</term>
<term>Total phospholipid</term>
<term>Total phospholipids</term>
<term>Ultrastructural changes</term>
<term>Untreated</term>
<term>Untreated animals</term>
<term>Untreated groups</term>
<term>Untreated hearts</term>
<term>Various enzyme activities</term>
<term>Various periods</term>
<term>Various time intervals</term>
<term>Ventricular</term>
<term>Ventricular arrhythmias</term>
<term>Ventricular fibrillation</term>
<term>Water content</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: The effects of chronic amiodarone therpy oon myocardial phospholipid hydrolysis induced by total in vitro ischaemia were investigated in cat hearts. Chronic treatment of cats with amiodarone (30 mg/kg/day, orally) for 6 weeks resulted in a sufficient uptake of the drug reaching tissue levels of 83 ± 13 & 122 ± 22 μm (n = 12) for amiodarone and its principle metabolite, desethylamiodamine, respectively. This was accompanied by a significant increase (37%, P<0.001) in total phospholipid content of heart in treated as compared to untreated animals. Upon in vitro total ischaemia, these endogenous drug levels were sufficient to attenuate significantly hydrolysis of membrane phospholipid. The degree of attenuation was dependent upon the duration of ischaemic insult. In this regard, protection against phospholipid losses by amiodarone treatment was significantly more in the later irreversible phase of ischaemic injury whether studied in an in vitro total ischaemia model or in an isolated perfused heart preparation. Similar trend was observed in the relative accumulation of lysophospholipid and non-esterified fatty acid levels during ischaemia, i.e. both were significantly attenuated by amiodarone treatment. However, in contrast to the fatty acid data, the net changes in lysophospholipids per gram tissue wet weight were similar in treated and untreated animals, suggesting that the protective effects of amiodarone may have involved other enzymes including phospholipase C and D. Also, during the entire time course studied, all the phospholipid classes appeared to be affected to more or less a similar degree, indicating that the effects of the drug may have manifested in other subcellular compartments besides lysosommes. However, at all time periods studied, the net release of eicosatetraenoic and docosahexaenoic acid (fatty acids occupying primarily sn-2 position of phospholipids) was different, release of the former fatty acid being inhibited more than the latter, suggesting specific interaction of amiodarone with the molecular species of phospholipid. The data suggest that amiodarone attenuates ischaemia-induced membrane lipid abnormalities in part through modulation of phospholipid metabolism, and that this effect may be one of the key determinants which contribute to its antiarrhythmic properties during acute ischaemia.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
<region>
<li>Ontario</li>
</region>
<settlement>
<li>Toronto</li>
</settlement>
<orgName>
<li>Université de Toronto</li>
</orgName>
</list>
<tree>
<country name="Canada">
<region name="Ontario">
<name sortKey="Shaikh, Nisar A" sort="Shaikh, Nisar A" uniqKey="Shaikh N" first="Nisar A." last="Shaikh">Nisar A. Shaikh</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E39 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E39 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:0F1479CA463F91A1600360B7A7C0731E37661866
   |texte=   Effect of amiodarone therapy on the time course of myocardial phospholipid hydrolysis during in vitro total ischaemia in cat hearts
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021